Patents Examined by Thea D'Ambrosio
  • Patent number: 10519239
    Abstract: Agents that inhibit the dimerization of a prototypic galectin such as galectin-7 are described. These agents, for example antibodies and peptides, bind to a domain corresponding to residues 13-25, 86-108 and/or 129-135 of human galectin-7. The use of such agents to inhibit a biological, physiological and/or pathological process that involves prototypic galectin dimerization, for example for the inhibition of galectin-7-mediated apoptosis and the treatment of galectin-7-expressing cancers, is also described.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: December 31, 2019
    Assignee: INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: David Chatenet, Nicolas Doucet, Yves St-Pierre, Maria-Claudia Vladoiu
  • Patent number: 10495642
    Abstract: The present invention relates to a method for identifying inhibitors of breast cancer metastasis based on a screening with proteins that are specific for the secretome of a chondrocyte, preferably cytokines and/or chemokines. The ligands as identified lead to a decrease of the migration and/or a re-differentiation of a breast cancer cell and/or a reduction of the number and/or size of breast cancer metastases. The present invention further relates to a method for detecting breast cancer metastasis, comprising the step of detecting at least one protein that is specific for the secretome of a chondrocyte, and for methods for treating and/or preventing breast cancer metastasis in a patient in need thereof, comprising the step of administering an effective amount of at least one ligand for one protein that is specific for the secretome of a chondrocyte to said patient in need thereof.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: December 3, 2019
    Assignee: ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG
    Inventors: Prasad Shastri, Jon Christensen, Xavier Lucas, Stefan Günther
  • Patent number: 10494401
    Abstract: The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the ?4?1 integrin on mesenchymal stem cells and for the surface of bone.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: December 3, 2019
    Assignee: The Regents of the University of California
    Inventors: Kit S. Lam, Ruiwu Liu, Wei Yao, Nancy Lane
  • Patent number: 10471058
    Abstract: The present invention relates to novel treatments of periodontal disease by administering a suitable formulation of a cyclophilin inhibitor. The present invention further relates to novel pharmaceutical compositions containing said cyclophilin inhibitor compounds.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: November 12, 2019
    Assignee: PERIOC LTD
    Inventors: Thomas Kissel, Ching Pong Mak
  • Patent number: 10471037
    Abstract: The present application in one aspect provide Fc-containing polypeptide conjugates comprising an Fc-containing polypeptide conjugated to a conjugate moiety, wherein the Fc-containing polypeptide comprises an N-glycosylated Fc region comprising an acceptor glutamine residue flanked by an N-glycosylation site and wherein the conjugate moiety is conjugated to the Fc-containing polypeptide via the acceptor glutamine residue. Also provided are methods of making such Fc-containing polypeptide conjugates by using a wildtype or engineered transglutaminases. Further provided are engineered transglutaminases specifically designed for carrying out such reactions.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: November 12, 2019
    Assignee: CSPC Dophen Corporation
    Inventors: Sean Hu, Lisha Allen
  • Patent number: 10426841
    Abstract: The present invention relates to a composition and a combination comprising at least one first drug and at least one protein-binding prodrug, wherein the protein-binding prodrug comprises a protein-binding group, a second drug, and a linker that can be cleaved hydrolytically, enzymatically, or in a pH-dependent manner in the body, as well as to a kit and a pharmaceutical composition comprising said composition or combination.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: October 1, 2019
    Assignee: Vergell Medical S.A.
    Inventor: Felix Kratz
  • Patent number: 10421797
    Abstract: The present invention relates to a short peptide-based therapeutic agent and a medicinal composition including the same for inhibiting activities of cancer cells, which includes at least one short peptide listed as SEQ ID NOs: 1 and 2, either of which is unglycosylated and has no more than 40 amino acid residues, thereby specifically reducing or inhibiting activities of cancer cells such as the cancer cell proliferation, cancer stemness, cell migration, cancer cell invasion, metastasis or drug resistance.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: September 24, 2019
    Assignee: NATIONAL CHENG KUNG UNIVERSITY
    Inventors: Ju-Ming Wang, Yu-Wei Hsiao, Jhih-Ying Chi
  • Patent number: 10357472
    Abstract: The present application in one aspect provide Fc-containing polypeptide conjugates comprising an Fc-containing polypeptide conjugated to a conjugate moiety, wherein the Fc-containing polypeptide comprises an N-glycosylated Fc region comprising an acceptor glutamine residue flanked by an N-glycosylation site and wherein the conjugate moiety is conjugated to the Fc-containing polypeptide via the acceptor glutamine residue. Also provided are methods of making such Fc-containing polypeptide conjugates by using a wildtype or engineered transglutaminases. Further provided are engineered transglutaminases specifically designed for carrying out such reactions.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: July 23, 2019
    Assignee: CSPC Dophen Corporation
    Inventors: Sean Hu, Lisha Allen
  • Patent number: 10344064
    Abstract: Compositions comprising peptide sequences with high cytotoxicity to cancer cell lines are provided. Pharmaceutical compositions comprising peptide sequences with high cytotoxicity to cancer cell lines are provided. A method for treating cancer is provided.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: July 9, 2019
    Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: A. James Link, Siyan Zhang
  • Patent number: 10328119
    Abstract: The present disclosure relates to lipoprotein complexes and lipoprotein populations and their use in the treatment and/or prevention of dyslipidemic diseases, disorders, and/or conditions. The disclosure further relates to recombinant expression of apolipoproteins, purification of apolipoproteins, and production of lipoprotein complexes using thermal cycling-based methods.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: June 25, 2019
    Assignee: CERENIS THERAPEUTICS HOLDING S.A.
    Inventors: Jean-Louis Dasseux, Rose Ackermann, Daniela Carmen Oniciu
  • Patent number: 10322163
    Abstract: The present disclosure relates to lipoprotein complexes and lipoprotein populations and their use in the treatment and/or prevention of dyslipidemic diseases, disorders, and/or conditions. The disclosure further relates to recombinant expression of apolipoproteins, purification of apolipoproteins, and production of lipoprotein complexes using thermal cycling-based methods.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: June 18, 2019
    Assignee: CERENIS THERAPEUTICS HOLDING S.A.
    Inventors: Jean-Louis Dasseux, Rose Ackermann, Daniela Carmen Oniciu
  • Patent number: 10308684
    Abstract: The present invention relates to a stapled peptide, a preparation method thereof and the use thereof, and more specifically to an amphipathic alpha-helical stapled peptide comprising hydrophobic amino acids and hydrophilic amino acids, a preparation method thereof, and the use thereof for intracellular delivery of an active substance.
    Type: Grant
    Filed: November 27, 2015
    Date of Patent: June 4, 2019
    Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Jaehoon Yu, Soonsil Hyun, Yan Lee, Seonju Lee
  • Patent number: 10286041
    Abstract: Provided herein are methods for prophylactic treatment of renal disorders comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual suspected of having, predisposed to, or at risk of developing a renal disorder.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: May 14, 2019
    Assignees: Mallinckrodt ARD IP Limited, Rhode Island Hospital
    Inventors: Steve Cartt, Rujun Gong
  • Patent number: 10287337
    Abstract: The present invention provides compositions, and methods for local administration of certain peptides or combination with certain small molecules that produce analgesia and anti-inflammation in a mammal. Exemplary polypeptides provide peripheral analgesia and anti-inflammation when administered via local topical, subcutaneous, intradermal, or intranasal administration, to provide analgesia and anti-inflammation. Through antagonism of peripheral CGRP receptors alone, or in combination with inhibition of sensory sodium channels or anti-inflammation, the compositions of the invention provide local therapeutic pain relief with minimal undesired systemic side effects in a subject. Also provided are improved peptide delivery techniques including microneedle unit dose administering apparatus and methods.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: May 14, 2019
    Assignee: AFASCI, Inc.
    Inventors: Xinmin Xie, Conrado Pascual, Xi Xie, James Xie
  • Patent number: 10287361
    Abstract: Methods of inhibiting platelet aggregation using antibodies having binding specificity for the ? subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing or treating thrombosis in a subject using such antibodies.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: May 14, 2019
    Inventor: Kai Yuan Xu
  • Patent number: 10273272
    Abstract: The present invention provides novel antimicrobial peptides and nucleic acids encoding them, the peptides having an inhibitory or bactericidal/bacteriostatic effect on both Gram-negative and Gram-positive bacteria. The invention includes methods of treating bacterial infections and preventing the spread of the infections or contamination by the infection. The peptides of the present invention are of particular use as therapeutics to treat Gram-negative infections and are of use in impregnation, covering or coating medical devices or implants or prosthetics prior to introduction into a patient's body.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: April 30, 2019
    Assignee: Amprologix Limited
    Inventors: Mathew Upton, Samantha Halliwell, Jeremy Derrick
  • Patent number: 10246485
    Abstract: The present invention relates to a method for concentrating von Willebrand Factor (VWF) from an aqueous solution comprising precipitating the VWF by providing calcium ions and phosphate ions and the subsequent resolubilization of the VWF by means of an aqueous solution comprising a calcium complexing compound.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: April 2, 2019
    Assignee: CSL LIMITED
    Inventors: Holger Lind, Sonja Beckmann-Scheld, Katharina Propp
  • Patent number: 10232019
    Abstract: Methods for treating hyperglycemia disorders in a subject in need thereof and pharmaceutical compositions for the treatment of hyperglycemia disorders are disclosed. The methods include administering an effective amount of apolipoprotein A-IV to the subject. Also disclosed are methods for substantially restoring glucose tolerance in a subject in need thereof to a normal level and methods for lowering blood glucose levels in a subject having hyperglycemic disorders, including insulin resistant disorders, such as prediabetes, metabolic syndrome, polycystic ovary disease, type A syndrome, gestational diabetes, and endocrine conditions associated with hyperglycemia, including Cushing's Disease, glucagon excess (glucagon secreting tumors) and acromegaly.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: March 19, 2019
    Assignee: University of Cincinnati
    Inventors: Patrick Tso, Fei Wang, Sean Davidson, Stephen Woods
  • Patent number: 10220101
    Abstract: The present invention relates to a composition and a combination comprising at least one first drug and at least one protein-binding prodrug, wherein the proteinbinding prodrug comprises a protein-binding group, a second drug, and a linker that can be cleaved hydrolytically, enzymatically, or in a pH-dependent manner in the body, as well as to a kit and a pharmaceutical composition comprising said composition or combination.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: March 5, 2019
    Assignee: Vergell Medical S.A.
    Inventor: Felix Kratz
  • Patent number: 10201584
    Abstract: This disclosure is directed to pharmaceutical compositions that comprise two or more therapeutic agents that, inter alia, are useful for inhibiting hepatitis C virus (HCV) and methods for inhibiting HCV by co-administering two or more anti-HCV therapeutic agents.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: February 12, 2019
    Assignee: ABBVIE INC.
    Inventors: Christine A. Collins, Daniel E. Cohen, Gennadiy Koev, Preethi Krishnan, Tami J. Pilot-Matias